ArticleProceedings of the National Academy of Sciences of the United States of America2008
IP6K2 is a client for HSP90 and a target for cancer therapeutics development.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Targeting the Ip6k2-Runx2 axis disrupts osteoblast-osteoclast coupling to treat osteoporosis.Nature communications · 2026Article
- Subtype-Specific mInternational journal of molecular sciences · 2026Article
- Integrating machine learning and molecular dynamics simulation to decipher the molecular network of dioxin-associated liposarcoma.Scientific reports · 2025Article
- Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.Cancer research · 2022Article
- Multiple substrate recognition by yeast diadenosine and diphosphoinositol polyphosphate phosphohydrolase through phosphate clamping.Science advances · 2021Article
- The inositol pyrophosphate pathway in health and diseases.Biological reviews of the Cambridge Philosophical Society · 2018Review
- Interferons as inducers of apoptosis in malignant cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2013Review
- Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors.Analytical biochemistry · 2013Article
- Obesity and cancer risk: evidence, mechanisms, and recommendations.Annals of the New York Academy of Sciences · 2012Review
- Molecular dynamics simulations of hsp90 with an eye to inhibitor design.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.Biochemical pharmacology · 2012Review
- Human calmodulin methyltransferase: expression, activity on calmodulin, and Hsp90 dependence.PloS one · 2012Article
- The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.Molecular cancer · 2010Article
- Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90.ACS medicinal chemistry letters · 2010Article
- Cancer and virus leads by HTS, chemical design and SEA data mining.Current topics in medicinal chemistry · 2009Review
- Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay.Bioorganic & medicinal chemistry letters · 2008Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.